Authors

Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

Latest:

The Future of Endometrial Cancer Treatment

Experts give insight on what they are looking forward to in the endometrial cancer space.

Victor Villalobos, MD, PhD, University of Colorado

Victor Villalobos, MD, PhD, University of Colorado Denver

Victor Villalobos, MD, PhD, University of Colorado School of Medicine

Victor Y. Yazbeck, MD

Latest:

Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLL

Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.

Victoria Atkinson, MD

Latest:

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

Victoria M. Villaflor, MD

Latest:

Clinical Scenario: Metastatic EBV-Positive NPC

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Victoria Villaflor, MD

Latest:

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Vidhya Karivedu, MD

Latest:

Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

Vidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.

Vijayalakshmi Iyer, PhD

Latest:

Defining Eligibility and Providing Counseling Key for Lung Cancer Screening Programs

Through detailing past programs and discussing how they've each addressed their own challenges, the American Thoracic Society and the American Lung Association's new lung cancer screening guide can help clinicians design, implement, conduct, and streamline lung cancer screening programs.

Vikram C. Gorantla, MD

Latest:

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Viktor Grünwald, MD, Medical School Hannover

Viktor Grunwald, MD, PhD

Latest:

Dr Grünwald on Tumor Burden Outcomes From the CLEAR Trial in Advanced RCC

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Vinay Gupta, MD

Latest:

Novel Proteasome Inhibitors for Multiple Myeloma

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Vince Calio

Latest:

Novel Antibody-Drug Conjugate Enters Phase III Trial for Metastatic TNBC

Investigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.

Vincent Chung, MD

Latest:

Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic Cancer

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Vincent J. Picozzi, MD

Latest:

Dr. Picozzi on Prognostic Value of Pathologic Response to Chemo in Pancreatic Cancer

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Vincent Lam, MD

Latest:

Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung Cancer

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

Vincent Miller, MD

Latest:

Dr. Vincent Miller Describes FoundationOne

Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes FoundationOne, a fully informative genomic profile that launched in 2012.

Vincent T. DeVita, Jr., MD

Latest:

Dr. DeVita Discusses "The Death of Cancer"

In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there. In an interview with OncLive hosted by Maurie Markman, MD, he speaks with DeVita on his book and his thoughts on how the field has evolved.